Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation". Learn more at: www.evogene.com.
Looking for a particular Evogene employee's phone or email?
The Evogene annual revenue was $5.1 million in 2026.
Ofer Haviv is the President and CEO of Evogene.
67 people are employed at Evogene.
Evogene is based in Rehovot, Central District.
The NAICS codes for Evogene are [5417, 541, 54, 54171, 541713, 541513, 513, 51, 54151, 5415].
The SIC codes for Evogene are [87, 873].